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Abstract Matrix metalloproteinase-9 (MMP-9) plays a
central role in the invasion and metastasis of various types
of cancer cells. Here, we demonstrate that glaucine, an al-
kaloid isolated from the plant Corydalis turtschaninovii
tuber (Papaveraceae), can inhibit the migration and invasion
of human breast cancer cells. We further show that glaucine
significantly blocks phorbol 12-myristate 13-acetate
(PMA)-induced MMP-9 expression and activity in a dose-
dependent manner. Results from reporter gene and elec-
trophoretic mobility shift assays revealed that glaucine in-
hibits MMP-9 expression by suppressing activation of the
nuclear transcription factor nuclear factor-jB (NF-jB).
Moreover, glaucine attenuates PMA-induced IjBa degra-
dation and nuclear translocation of NF-jB. Finally, we also
found that glaucine inhibits invasion and MMP-9 expres-
sion in the highly metastatic MDA-MB-231 breast cancer
cell line. Taken together, our findings indicate that the
MMP-9 inhibitory activity of glaucine and its abilities to
attenuate IjBa and NF-jB activities may be therapeutically
useful as a novel means of controlling breast cancer growth
and invasiveness.
Keywords Invasion  Migration  MMPs  Natural
compound  Breast cancer
Introduction
Metastasis is a defining characteristic of malignant cancer
cells, and uncontrolled metastasis is the leading cause of death
in patients with cancer. Metastasis is a multi-step process in-
volving degradation of the extracellular matrix (ECM), ad-
hesion of cancer cells to endothelial cells, extravasation
leading to infiltration of the underlying tissue, and metastatic
foci formation [1, 2]. When tumor cells metastasize, a number
of proteolytic enzymes contribute to the degradation of ECM
components and the basement membrane [3, 4].
Matrix metalloproteinases (MMPs) are a family of zinc-
dependent endopeptidases that degrade ECM components
and are therefore important in several physiological and
pathological functions, including tumorigenesis and cancer
metastasis [5, 6]. At least 20 types of MMPs have been
identified to date, and MMP-2 and -9 are highly correlated
with tumor invasiveness and metastatic potency [7]. Var-
ious pathological processes such as tumor invasion,
atherosclerosis, inflammation, and rheumatoid arthritis can
stimulate MMP-9 synthesis and secretion, whereas MMP-2
is usually constitutively overexpressed [8, 9]. Base on re-
ports from several different laboratories, basal MMP-9
levels in most cancer cell lines are usually low, and its
expression can be induced by treatment with cytokines and
phorbol 12-myristate 13-acetate (PMA), which activates
transcription factors such as nuclear factor (NF)-jB and
activator protein (AP)-1 [10]. Thus, MMP-9 is an attractive
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target to decrease the invasiveness and metastasis of can-
cers that overexpress this protein.
Glaucine [(S)-(?)-1,2,9,10-tetramethoxyaporphine] is
an alkaloid isolated from the plant Corydalis turtschani-
novii tuber (Papaveraceae) that has been used for years as a
traditional folk remedy for cough and for its spasmolytic,
neuropharmacologic, hypothermic, and blood pressure-
lowering activities [11–13]. Glaucine is also known to in-
hibit the proliferation of a variety of tumor cells, including
leukemia, cervical, bladder, breast, and colon cancer cells
[14–16]. In addition, glaucine seems to exert chemopre-
ventive properties against melanoma, and it also suppresses
tumor migration [17]. However, the molecular mechanism
underlying the beneficial effects of glaucine are not yet
fully understood. In this study, we investigated how glau-
cine treatment affected MMP-9 expression in breast cancer
cells and explored the underlying upstream signaling
mechanisms. We found that glaucine significantly inhibited
MMP-9 gene expression by suppressing NF-jB activation,
which subsequently reduced the invasion and migratory
abilities of human breast cancer cells.
Materials and methods
Cells and reagents
The human breast cancer cell line MCF-7 and MDA-MB-231
cells (ATCC, Manassas, VA, USA) were maintained in RPMI
1640 supplemented with 10 % heat-inactivated FBS
(HyClone, Logan, UT, USA), penicillin (100 U/ml), and
penicillin–streptomycin (100 lg/ml) at 37 C with 5 % CO2
atmosphere in a humidified incubator. Glaucine was obtained
from MP Biomedicals Korea (Seoul, Korea). Gelatin was
obtained from DIFCO (Lexington, KY, USA). Lipofectamine
2000 reagent was purchased from Invitrogen (Carlsbad, CA,
USA). PMA was purchased from Calbiochem (La Jolla, CA,
USA). Anti-MMP-9 antibody was purchased from Abcam
(Cambridge, United Kingdom). All the chemicals not in-
cluded above were from Sigma (St. Louis, MO, USA).
Cell proliferation and viability assay
All proliferation and viability assays were based on the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) method. Cells were seeded in a 96-well plate
at a density of 1 9 104 cells/well. The cells were treated
with various concentration of glaucine and allowed to grow
for 24 and 48 h. At the end of the experiment, the media
was removed and DMSO was added with MTT solubi-
lization solution. Absorbance was measured at 550 nm
(SpectraMAX 340PC; Molecular Devices, Sunnyvale, CA,
USA).
Colony-forming assay
MCF-7 cells were seeded into 6-well plate and allowed to
attach for 24 h at 37 C in culture medium. Cells were then
treated with various concentration of glaucine. After
4 days, colonies were fixed with fixing solution (metha-
nol:acetic acid = 3:1) for 10 min at room temperature and
stained with 0.01 % crystal violet solution. Plates were
washed with PBS and were photographed (Olympus Mi-
croscope System IX51; Olympus, Tokyo, Japan).
In vitro invasion assay
Matrigel invasion assays were used to assess the effect of
glaucine in MCF-7 or MDA-MB-231 cells. The 8-lm pore-
size polycarbonate nucleopore filter inserts in a 24-well
transwell chamber (BD Biosciences, San Jose, CA, USA)
was coated with 30 lg/well matrigel (Sigma). Glaucine-
treated MCF-7 cells were seeded into the upper part of the
matrigel-coated filter, and serum-free RPMI with or with-
out 100-nM PMA was added to the lower part. After 36 h,
the cells that had migrated through the matrigel and the
8-lm pore-size membrane were fixed, stained, and counted
under a light microscope (Olympus Microscope System
IX51; Olympus, Tokyo, Japan).
RNA extraction and semi-quantitative RT-PCR
Total RNA was extracted from cells with Trizol (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s pro-
tocol. Approximately 2 lg of total RNA was used to prepare
cDNA using the Superscript First Strand cDNA Synthesis
Kit (Bioneer, Daejeon, South Korea). The following primers
were used in this study: 50-TCCCTGGAGACCTGA-
GAACC-30 and 50-CGGCAAGTCTTCCGAGTAGTT-30
for MMP-9; 50-CCATCACCATCTTCCAGGAG-30 and 50-
CCTGCTTCACCACGTTCTTG-30 for GAPDH. PCR was
performed with Platinum Tap polymerase (Invitrogen) under
the following conditions: 30 cycles of 96 C for 40 s, 55 C
(MMP-9) or 60 C (GAPDH) for 40 s, and 72 C for 1 min
followed by 10 min at 72 C. The PCR products were
electrophoresed on a 2 % (w/v) agarose gel in 1 9 Tris–
acetate-EDTA (TAE) buffer and stained with ethidium
bromide solution.
Gelatin zymography
The presence of MMP-9 in the supernatants of DMSO or
glaucine-treated MCF-7 cells was analyzed with gelatin
zymograms. Briefly, cells were incubated in serum-free
RPMI and the supernatants were collected after incubation
for 24 h, clarified by centrifugation, normalized to the total
protein concentration of the cell lysate, mixed with non-
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reducing Laemmli sample buffer, and separated by elec-
trophoresis in 10 % SDS-PAGE containing 1 mg/ml ge-
latin (DIFCO). After electrophoresis, gels were re-natured
by washing in 2.5 % Triton X-100 solution twice for
30 min to remove all SDS. The gels were then incubated in
50 mmol/L Tris–HCl (pH 7.4), 5 mmol/L CaCl2, and 1 lM
ZnCl2 at 37 C overnight. After incubation, the gels were
stained with 0.05 % Coomassie brilliant blue R-250 for
30 min at room temperature and then destained in distilled
water. MMP-9 activities were visible as clear bands on a
blue background where the gelatin substrate had been hy-
drolyzed by enzyme activity.
ELISA assay
The supernatants were collected for measuring secreted
MMP-9 protein. The total MMP-9 protein was assayed
according to SensoLyte PlusTM 520 MMP-9 assay system
(AnaSpec, San Jose, CA). MMP-9 activity unit was ex-
pressed as a change in fluorescence intensity at excitation
of 490 nm/emission of 520 nm (SpectraMAX 340PC;
Molecular Devices, Sunnyvale, CA, USA).
Transient transfection and luciferase reporter assay
The transcriptional activities of MMP-9, mNF-jB MMP-9,
and NF-jB were measured by luciferase reporter assay
using the pMMP-9-Luc, mNF-jB MMP-9, and pNF-jB-
Luc reporter plasmids. MCF-7 cells were seeded into
12-well plates. Cells at 70–80 % confluence were co-
transfected with 0.2 lg of MMP-9, or NF-jB reporter
constructs and 0.2 lg pSV-b-galatosidase for 24 h. The
transfected cells were incubated with glaucine and then
stimulated with 100 nM PMA for 9 h. Luciferase and b-
galactosidase activities were assayed according to the
manufacture’s protocol (Promega), using a Luminometer
20/20n (Turner BioSystems, Sunnyvale, CA, United
States). Luciferase activity was normalized by b-galac-
tosidase activity in cell lysate and expressed as an average
of three independent experiments.
Cell fraction and immunoblotting
Nuclear and cytosolic factions were prepared using Nu-
clear and Cytoplasmic Extraction Reagents kit (Fermen-
tas). PCNA and Tubulin were used as markers for nuclear
and cytosol proteins, respectively. Lysate proteins were
resolved by SDS-PAGE and transferred onto nitrocellulose
membranes. The membranes were incubated with TBS
containing 0.1 % Tween 20 and 5 % skimmed milk, and
then exposed to the desired primary antibodies. After
treatment with anti-rabbit or -mouse antibodies conjugated
with horseradish peroxidase, the immunoreactive bands
were visualized by standard ECL method.
Electrophoretic mobility shift assay (EMSA)
Double-stranded oligonucleotides containing the NF-jB (50-
AGTTGAGGGGACTTTCCCAGGC-30) or consensus se-
quences were 50-end-labeled with c-32P ATP using T4
polynucleotide kinase. Unincorporated nucleotide was re-
moved by passage over a Bio-Gel P-6 spin column (Bio-Rad,
Inc., Hercules, CA). Nuclear extract was incubated with ra-
diolabeled probe for 20 min, and protein-DNA complexes
were separated from free probes by electrophoresis on a 4 %
native polyacrylamide gel in 0.5 3 Tris–HCl (pH 7.5), 1 mM
MgCl2, 50 mM NaCl, 0.5 mM EDTA, 4 % glycerol, 0.5 mM
DTT, and 50 mg/ml of poly (dI-dC). Dried gels were visu-
alized by autoradiography.
Statistics analysis
Statistical analysis was performed by computer program
Prism (GraphPad Software, La Jolla, CA). The results are
presented as mean ± SE. The statistical significance of dif-
ferences between groups was analyzed via repeated measures
of one-way analysis of variance followed by Student’s t test.
A P value B 0.05 was considered to be significant.
Results
Effects of glaucine on the growth of PMA-treated
MCF-7 cells
We first examined the effects of glaucine on PMA-induced
MCF-7 cell proliferation using MMT assays. Treatment with
PMA for 24 and 48 h significantly increased MCF-7 cell
viability; however, treatment with [15 lM glaucine de-
creased cell proliferation in the presence or absence of PMA
(Fig. 1b). We performed colony formation assays to further
investigate the inhibitory effects of glaucine on cell prolif-
eration. PMA markedly enhanced the colony-forming ability
of MCF-7 cells compared to untreated cells (Fig. 1c). In
contrast, glaucine at 15 and 30 lM inhibited PMA-induced
colony formation by 48 and 63 %, respectively (Fig. 1c).
Effects of glaucine on migration and invasion in PMA-
treated MCF-7 cells
Cell migration is a critical process during many stages of
cancer cell metastasis [18]. We, therefore, determined whe-
ther glaucine inhibited the invasive behavior of breast cancer
cells. As shown in Fig. 2a, glaucine significantly suppressed
the migration of PMA-treated MCF-7 cells. To further explore
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the effect of glaucine on invasion, PMA-induced cells were
treated with glaucine (15 or 30 lM), and cell invasion was
determined after 36 h. As shown in Fig. 2b, glaucine
markedly decreased PMA-induced MCF-7 cell invasion in a
dose-dependent manner, indicating that glaucine is an effec-
tive inhibitor of breast cancer cell migration and invasion.
Effects of glaucine on PMA-induced expression
and proteolytic activity of MMP-9
MMP-9 is an important ECM-degrading enzyme that has
been reported to be involved in cancer cell invasion and
migration [5, 6]. To determine whether MMP-9 activity is
involved in the PMA-induced invasion of MCF-7 cells, we
treated cells with PMA, a primary antibody against MMP-9,
or 30 lM glaucine, alone or in combination. Treatment with
MMP-9 primary antibody and 30 lM glaucine significantly
inhibited PMA-induced cell invasion (Fig. 3a). We also
investigated the effects of glaucine on MMP-9 gene ex-
pression. As shown in Fig. 3b, PMA induced MMP-9
mRNA and protein expression in MCF-7 cells, whereas
treatment with glaucine dose-dependently suppressed PMA-
induced MMP-9 gene expression. We next examined the
effects of glaucine on the secretion and proteolytic activity
Fig. 1 Glaucine suppresses
PMA-induced proliferation and
invasion of MCF-7 cells.
a Chemical structure of
glaucine. b MCF-7 cells were
treated with 0–50 lM glaucine
in the absence or presence of
100 mM PMA for 24 h (white
bars) and 48 h (black bars), and
cell viability was measured
using a MMT assay; *P \ 0.05,
**P \ 0.01 versus vehicle
alone-treated cells, #P \ 0.05
versus PMA alone-treated cells.
c MCF-7 cells were treated with
the indicated concentration
glaucine for 30 min and then
incubated with 100 nm PMA
for 4 days. After 4 days,
colonies were fixed with fixing
solution for 10 min at room
temperature and stained with




magnification was 9 100. Scale
bars, 100 lm. The number of
colonies from triplicate plates
was quantified using Image J;
#P \ 0.01 versus vehicle alone-
treated cells, *P \ 0.01 versus
PMA alone-treated cells
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of MMP-9 in conditioned media. ELISA and gelatin zy-
mography results revealed that glaucine inhibited PMA-in-
duced MMP-9 secretion and proteolytic activity (Fig. 3c).
Collectively, these finding indicate that glaucine suppressed
PMA-induced MMP-9 expression at both the protein and
mRNA levels and subsequently inhibited MMP-9 enzymatic
activity.
Glaucine inhibits MMP-9 transcriptional activity
by suppressing PMA-stimulated NF-jB activity
NF-jB plays an important role in regulating MMP-9 ex-
pression in various cancer cell lines [19]. We examined the
effects of glaucine on the binding of this transcription
factor to the MMP-9 promoter. A luciferase reporter gene
containing the MMP-9 promoter region (-925/?13) was
transiently transfected into MCF-7 cells, and luciferase
activity was determined. MMP-9 promoter activity in cells
treated with PMA was upregulated by 3.3-fold compared
with that in untreated cells. Glaucine inhibited PMA-in-
duced MMP-9 promoter activity in a dose-dependent
manner (Fig. 4a). The transcription factor binding sites in
the MMP-9 promoter include sites for NF-jB (-600 bp)
[20]. To determine whether NF-jB is involved in MMP-9
transcription regulation, we generated a MMP-9 promoter
with a mutation in the NF-jB (-600 bp) binding site. The
results of the reporter gene assay showed that PMA-in-
duced promoter activity of the mutated promoter in the NF-
jB biding site (-925/? 13) was not affected by glaucine
(Fig. 4b). We also performed experiments using luciferase
reporter vectors containing tandem repeats of the NF-jB
binding sites and observed dose-dependent reductions in
Fig. 2 Glaucine inhibits the migration and invasion of PMA-treated
MCF-7 cells. a PMA-induced MCF-7 cells were scratched with a
pipette tip and incubated with the indicated concentration of glaucine
for 36 h. The wound area was quantified by measuring the cell-free
area. Original magnification was 9 100. Scale bars, 100 lm. Cell
migration into the wound area is represented as the percentage of
recovery relative to 0 h. #P \ 0.01 versus vehicle alone-treated cells,
*P \ 0.01 versus PMA alone-treated cells. b MCF-7 cells were
incubated with 100-nM PMA and the indicated concentration of
glaucine for 36 h. The invasion ability of MCF-7 cells was
determined by a Matrigel invasion assay. Original magnification
was 9 200. Scale bars, 100 lm. The cell invasion ability was
quantified; #P \ 0.01 versus vehicle alone-treated cells, *P \ 0.01
versus PMA alone-treated cells. Data represent the mean ± SE of
three independent experiments
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luciferase activity in cells transfected with the NF-jB re-
porter, following glaucine treatment (Fig. 4c). These re-
sults indicated that NF-jB binding to the MMP-9 promoter
region contributed to the inhibitory effect of glaucine on
PMA-induced MMP-9 transcription.
Effects of glaucine on NF-jB binding in the MMP-9
promoter
We next performed EMSAs to determine the effect of
glaucine on the DNA-binding activity of NF-jB. As shown
in Fig. 5a, PMA induced NF-jB DNA-binding activity,
which was dose-dependently reduced by glaucine. To
confirm this observation, we analyzed p65 levels in the
cytosolic and nuclear fractions. The results showed that
PMA increased IjBa phosphorylation in the cytoplasm,
leading to increased nuclear translocation of the NF-jB
p65 subunit (Fig. 5b). However, glaucine inhibited PMA-
induced phosphorylation of IjBa in a dose-dependent
manner (Fig. 5b) and decreased nuclear NF-jB p65 sub-
unit levels (Fig. 5b, right panel). These results indicate that
glaucine inhibits NF-jB activation by suppressing IjBa
phosphorylation and the subsequent nuclear translocation
of NF-jB in PMA-treated MCF-7 cells.
Glaucine suppresses MDA-MB-231 cells invasion
by inhibiting MMP-9 through the NF-jB pathway
The results obtained in MCF-7 cells suggested that glau-
cine inhibits PMA-induced MMP-9 expression by
Fig. 3 Glaucine reduces PMA-
induced expression and
secretion of MMP-9 in MCF-7
cells. a MCF-7 cells were
incubated in Matrigel-coated
transwell with or without PMA
and anti-MMP-9 antibody or
30 lM glaucine for 36 h. The
cell invasion ability was
quantified; #P \ 0.001 versus
vehicle alone-treated cells,
*P \ 0.01, **P \ 0.001 versus
PMA alone-treated cells. Data
represent the mean ± SE of
three independent experiments.
b MCF-7 cells were incubated
with the indicated concentration
of glaucine for 30 min followed
by 100-nM PMA stimulation for
24 h. After 24 h, the protein
level and the mRNA level of
endogenous MMP-9 were
measured by western blotting
(Top and 2nd panels) and RT-
PCR (3rd and bottom panel).
Tubulin and GAPDH was used
as an internal control. c MCF-7
cells were pretreated with
glaucine for 30 min and
stimulated with 100-nM PMA
for 24 h. After 24 h, the
conditioned medium was
collected and assayed for the
secreted MMP-9 using gelatin
zymography and ELISA;
#P \ 0.001 versus vehicle
alone-treated cells, *P \ 0.01
versus PMA alone-treated cells.
Data represent the mean ± SE
of three independent
experiments
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suppressing the nuclear translocation of NF-jB. To
demonstrate the functional consequence of glaucine in
metastatic breast cancer, we used it to treat MDA-MB-231
cells, a highly metastatic breast cancer cell line that highly
expresses MMP-9 and constitutively activated NF-jB [21,
22]. MDA-MB-231 cells were incubated with glaucine
(0–30 lM), and we monitored changes in MMP-9 ex-
pression. As shown in Fig. 6a, treatment with glaucine for
24 h decreased MMP-9 expression in a dose-dependent
manner, as measured by western blotting and RT-PCR. We
further assessed the MMP-9 secretion in glaucine-treated
MDA-MB-231 cells by zymography and ELISA. The re-
sults revealed that glaucine inhibited MMP-9 secretion and
proteolytic activity (Fig. 6b). These findings support the
results we obtained in PMA-induced MCF7 cells (Fig. 3).
To assess the effects of glaucine on NF-jB translocation
further, we performed western blots of different subcellular
fractions to show that p65 nuclear translocation was sub-
stantially augmented after glaucine treatment (Fig. 6c top
panel). Finally, we performed invasion assays and found
that glaucine significantly inhibited MDA-MB-231 cell
invasion in a dose-dependent manner (Fig. 6d). Taken to-
gether, our findings demonstrate that glaucine inhibits
breast cancer cell migration and invasion by inhibiting NF-
jB-mediated MMP-9 transcription.
Discussion
For centuries, people have been harnessing the power of
nature to provide medicinal solutions to various diseases.
Indeed, in the context of cancer, plants in particular are the
rich sources of natural compounds that possess anticancer
activity and are used as novel lead compounds and
bFig. 4 Glaucine inhibits the transcriptional activity of MMP-9
promoter via suppression of PMA-stimulated NF-jB activity.
a MCF-7 cells were transfected with the pMMP-9-luciferase and
the pSV40-b-galactosidase vectors. The transfected cells were treated
with the indicated concentrations of glaucine for 30 min and
stimulated with 100 nM PMA for 9 h. The luciferase activity was
normalized by b-galactosidase activity. Each value represents the
mean ± SD of three independent experiments and is expressed
relative to a control. b MCF-7 cells were transfected with NF-jB
binding site mutant (mNF-jB) MMP-9-Luc. The transfected cells
were treated with glaucine for 30 min and stimulated with 100 nM
PMA for 9 h. The luciferase activity was normalized by b-galactosi-
dase activity. Each value represents the mean ± SD of three
independent experiments and is expressed relative to a control.
One-way ANOVA was performed to determine statistical significance
(*P \ 0.05). c MCF-7 cells were transfected with the reporter
plasmids containing tandem NF-jB binding sites. After 24 h, cells
were treated with or without 100 nM PMA for 9 h and the luciferase
activities were determined. Each value represents the mean ± SD of
three independent experiments and is expressed relative to a control.
One-way ANOVA was performed to determine statistical significance
(*P \ 0.05)
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chemical entities to derive superior new compounds. In this
study, we investigated whether glaucine could inhibit hu-
man breast cancer cell migration and invasion. We
demonstrated that: (a) glaucine inhibits migration and in-
vasion, (b) regulates MMP-9 expression and activity, and
(c) specifically abrogates NF-jB activation in both PMA-
treated MCF-7 cells and MDA-MB-231 cells.
Cancer invasion and metastasis are major properties of
various malignant tumors and the main causes of treatment
failure. A vital step in the invasive processes is the prote-
olytic degradation of the ECM by proteolytic enzymes such
as MMPs [5, 6]. In particular, MMP-9 overexpression has
been associated with the progression and invasion of dif-
ferent types of tumors, including mammary tumors [23].
Thus, agents and/or natural plant products that inhibit both
MMP-9 expression and activity have received considerable
attention for their potential use in the treatment of malig-
nant and invasive cancers [8].
Our results indicate that glaucine is a potent inhibitor
of PMA-induced MMP-9 expression in two breast cancer
cell lines (MCF-7 and MDA-MB-231), suggesting that the
ability of glaucine to inhibit MMP-9 expression may be a
general phenomenon. western blotting, RT-PCR, and lu-
ciferase reporter gene assays revealed that the target of
the inhibitory effect of glaucine was MMP-9 gene
transcription.
As described in a previous study, we found that PMA
stimulated MMP-9 expression and secretion [24, 25]. This
is in accordance with our observation that glaucine inhib-
ited the PMA-induced secretion of MMP-9 in a dose-de-
pendent manner by suppressing the transcriptional activity
of the MMP-9 gene in MCF-7 cells. Glaucine also dose-
Fig. 5 Glaucine inhibits the NF-jB activity in PMA-stimulated
MCF-7 cells. a MCF-7 cells were pretreated with the indicated
concentration of glaucine for 30 min and incubated with 100 nM
PMA for 30 min. Nuclear extracts were prepared and incubated with
radiolabeled oligonucleotides containing the NF-jB motif in the
MMP-9 promoter. b MCF-7 cells were pretreated with the indicated
concentration of glaucine for 30 min and incubated with 100-nM
PMA for 30 min. Cells were harvested and fractionated into the
cytoplasm and the nucleus. Lysates were then separated on a 10 %
SDS–polyacrylamide gel and subjected to western blotting with anti-
p65, anti-p-IjBa, and anti-IjBa antibodies. The analysis was
repeated in three times, and a-tubulin and PCNA were used as
markers for the cytoplasmic and nuclear fractions. The NF-jB protein
level that was translocated to the nucleus was quantified by
densitometric analyses. The bars represent the mean ± SD. One-
way ANOVA was performed to determine statistical significance
(*P \ 0.05)
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dependently inhibited the enzymatic activity of MMP-9
secreted from PMA-induced MCF-7 cells, suggesting that
it is a strong candidate for decreasing tumor metastasis and
invasion via dual inhibition of MMP-9 gene transcription
and enzyme activity.
The MMP-9 promoter region contains the NF-jB
binding site [25], and we showed that this site was neces-
sary for glaucine’s ability to inhibit MMP-9 expression in
both PMA-treated MCF-7 cells and MDA-MB-231 cells
which have constitutively activated NF-jB. This protein
complex is closely linked to inflammation, tumor cell
proliferation, survival, invasion, and metastasis [26, 27].
Notably, NF-jB is constitutively activated in many cancers
and contributes to resistance to chemo- and radiotherapies
by promoting the expression of anti-apoptotic proteins
[28]. Here, we demonstrated that glaucine suppressed
MMP-9 expression by inhibiting NF-jB activity in PMA-
treated MCF-7 and MDA-MB-231 cells.
In conclusion, we provide novel evidence that glaucine
suppresses breast cancer cell invasion and migration by
Fig. 6 Glaucine inhibits the invasion of MDA-MB-231 cells by
inhibiting MMP-9 expression and secretion through the NF-jB
pathway. a MDA-MB-231 cells were treated with the indicated
concentration of glaucine for 24 h. After 24 h, the protein level and
the mRNA level of endogenous MMP-9 were determined by western
blotting (Top and 2nd panels) and RT-PCR (third and bottom panel).
Tubulin and GAPDH was used as an internal control. b MDA-MB-
231 cells were treated with the indicated concentration of glaucine for
24. After 24 h, the conditioned medium was collected and assayed for
the secreted MMP-9 using gelatin zymography and ELISA; *P \ 0.01
versus vehicle control cells. Data represent the mean ± SE of three
independent experiments. c MDA-MB-231 cells were treated with the
indicated concentration of glaucine for 4 h. The cells were harvested
and fractionated into the cytoplasm and the nucleus. Lysates were
then separated on a 10 % SDS–polyacrylamide gel and subjected to
western blotting with anti-p65, anti-p-IjBa, and anti-IjBa antibodies.
The analysis was repeated in three times, and a-tubulin and PCNA
were used as markers for the cytoplasmic and nuclear fractions.
d MDA-MB-231 cells were treated with the indicated concentration
of glaucine for 36 h. The invasive ability of cells determined using
Matrigel-coated transwell. The cell invasion ability was quantified;
*P \ 0.001 versus vehicle alone-treated cells. Data represent the
mean ± SE of three independent experiments
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inhibiting MMP-9 activity and expression, which was due
to the blocking of NF-jB activation. An increasing number
of natural products possessing anticancer properties have
been unveiled in recent years. Once their antitumor
mechanisms are elucidated, these compounds could be
used in clinical chemotherapeutic strategies. In view of the
impressive in vitro potency of glaucine in reversing PMA-
induced cancer cell invasion at non-cytotoxic concentra-
tions (data not shown) and the fact that specific anti-
metastatic agents with minimal or no complications due to
cytotoxicity are preferred, naturally occurring phyto-
chemicals are indeed worthy of further development as
anti-metastatic agents for clinical use.
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